Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. Melanotan Ii
2. 121062-08-6
3. Upf5cj93x7
4. Dtxsid90153135
5. L-lysinamide, N-acetyl-l-norleucyl-l-alpha-aspartyl-l-histidyl-d-phenylalanyl-l-arginyl-l-tryptophyl-, Cyclic (2-7)-peptide
6. Refchem:925444
7. Dtxcid3075626
8. Mt-ii
9. Melanotan (mt)-ii
10. Melatonan
11. Melanotan Ii Acetate Salt
12. Chembl430239
13. (3s,6s,9r,12s,15s,23s)-15-[[(2s)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide
14. C50h69n15o9
15. (3s,6s,9r,12s,15s,23s)-12-((1h-imidazol-5-yl)methyl)-3-((1h-indol-3-yl)methyl)-15-((s)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide
16. Mtii
17. Melanotanii
18. Melanotan Ii?
19. Ac-nle-cyclo[asp-his-d-phe-arg-trp-lys]-nh2
20. Unii-upf5cj93x7
21. Melanotan Ii [who-dd]
22. Ebi_340792
23. Gtpl1323
24. Orb1296657
25. Schembl1047531
26. Schembl29473785
27. Chebi:195326
28. Ex-a7394
29. Hy-p0267
30. 121062-08-6 (non-salt)
31. Bdbm50027084
32. Bdbm50184359
33. Mfcd06795842
34. Akos015994654
35. Hs-2017
36. Ncgc00167281-01
37. Da-55328
38. Fa109114
39. F93947
40. 062m086
41. Q423855
42. Acetyl-(nle4,asp5,d-phe7,lys10)-cyclo-alpha-msh (4-10) Amide
43. (3s,6s,9r,12s,15s,23s)-12-((1h-imidazol-5-yl)methyl)-3-((1h-indol-3-yl)methyl)-15-((s)-2-acetamidohexanamido)-9-benzyl-6-(3-((diaminomethylene)amino)propyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide
44. (3s,6s,9r,12s,15s,23s)-15-((s)-2-acetylamino-hexanoylamino)-9-benzyl-6-(3-guanidino-propyl)-12-(3h-imidazol-4-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18hexaaza-cyclotricosane-23-carboxylic Acid Amide
45. (3s,6s,9r,12s,15s,23s)-15-[(n-acetyl-l-norleucyl)amino]-9-benzyl-6-{3-[(diaminomethylidene)amino]propyl}-12-[(1h-imidazol-5-yl)methyl]-3-[(1h-indol-3-yl)methyl]-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide
46. (3s,6s,9r,12s,15s,23s)-15-[[(2s)-2-acetamidohexanoyl]amino]-9-benzyl-6-(3-guanidinopropyl)-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide
47. (3s,6s,9r,12s,15s,23s)-9-benzyl-6-{3-[(diaminomethylidene)amino]propyl}-15-[(2s)-2-acetamidohexanamido]-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide
48. L-lysinamide, N-acetyl-l-norleucyl-l-.alpha.-aspartyl-l-histidyl-d-phenylalanyl-l-arginyl-l-tryptophyl-, Cyclic (2->7)-peptide
| Molecular Weight | 1024.2 g/mol |
|---|---|
| Molecular Formula | C50H69N15O9 |
| XLogP3 | 0 |
| Hydrogen Bond Donor Count | 13 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 17 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 385 |
| Heavy Atom Count | 74 |
| Formal Charge | 0 |
| Complexity | 1950 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE